PFS and OS univariable analysis of the clinical and blood-based parameters at baseline
| Progression-free survival | Overall survival | |||
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Clinical data | ||||
| Age | 1 (0.98 to 1) | 0.876 | 1 (1 to 1) | 0.063 |
| ECOG (0 vs ≥1) | 1.9 (1.1 to 3.3) | 0.031 | 2.9 (1.4 to 5.3) | 0.002 |
| Brain metastasis (yes vs no) | 1.5 (0.89 to 2.6) | 0.128 | 2 (1 to 3.8) | 0.048 |
| Number of prior therapies (0 vs ≥1) | 1.4 (0.79 to 2.3) | 0.26 | 1.1 (0.55 to 2.1) | 0.843 |
| BRAF mutation (yes vs no) | 0.52 (0.29 to 0.94) | 0.031 | 0.45 (0.21 to 0.98) | 0.043 |
| Treatment (combi-therapy vs monotherapy) | 1.3 (0.73 to 2.4) | 0.36 | 1.1 (0.55 to 2.4) | 0.724 |
| Biological data | ||||
| LDH | 1 (1 to 1) | 0.25 | 1 (1 to 1) | 0.09 |
| S100 | 1 (0.9 to 1.2) | 0.57 | 0.88 (0.67 to 1.2) | 0.381 |
| CRP | 1.04 (1 to 1.1) | 0.007 | 1.04 (1 to 1) | 0.004 |
| NLR | 1 (0.86 to 1.3) | 0.686 | 0.99 (0.8 to 1.2) | 0.956 |
| Platelets | 1 (1 to 1) | 0.741 | 1 (1 to 1) | 0.93 |
| D-dimers | 1.1 (1 to 1.2) | <0.001 | 1.1 (1 to 1.2) | 0.006 |
| ADAMTS13 activity | 0.99 (0.97 to 1) | 0.263 | 0.97 (0.94 to 1) | 0.022 |
| vWF:Ag | 1.04 (1 to 1.1) | 0.007 | 1.04 (1 to 1.1) | 0.043 |
Age and biological parameters are interrogated as continuous variables.
ECOG, Eastern Cooperative Oncology Group; NLR, neutrophil-to-lymphocyte ratio; vWF, von Willebrand factor.